Fed. Circ. OKs Ax Of Lilly's Axiron Patent, Allows Generics

Law360, New York (November 22, 2017, 6:42 PM EST) -- The Federal Circuit ruled Wednesday that a key claim of an Eli Lilly & Co. patent on the testosterone drug Axiron is invalid, upholding a lower court ruling that spurred the generics makers accused of infringement to launch their own versions of the drug.

The appeals court praised the over 200-page “thorough, well-considered opinion” that Judge Sarah Evans Barker of the Southern District of Indiana, Lilly’s home district, issued last year after a nine-day bench trial.

The judge correctly sided with Perrigo Co., Teva Pharmaceutical Industries Ltd....
To view the full article, register now.




Case Information

Case Title

Eli Lilly and Company v. Perrigo Company

Case Number



Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 24, 2016

Law Firms


Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.